Reducing the risk of stroke in patients with nonvalvular atrial fibrillation with direct oral anticoagulants. is one of these not like the others

Paul P. Dobesh, John Fanikos

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and increases risk of stroke by nearly 5-fold. While warfarin has been employed successfully to reduce the risk of stroke in these patients, there are a number of challenges with therapy. These include the need for therapeutic monitoring due to variability in patient response, frequent dose adjustments, numerous drug-drug, drug-food, and drug-disease interactions, and a heightened risk of thrombosis and bleeding due to these issues. Current guidelines recommend that the Vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs) should be used for thromboprophylaxis in patients with nonvalvular AF at risk for stroke or systemic embolic events. The DOACs include the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. In clinical trials these agents consistently demonstrated a reduction in the risks of hemorrhagic stroke and intracranial hemorrhage compared to VKA. Clinicians now must decide if there are meaningful differences between these agents in order to prescribe the best agent for an individual patient. Therefore, it is critical for clinicians to go beyond information provided in manuscript abstracts, and gain an understanding of the similarities and differences in clinical trial design, patient enrollment, and statistical analysis.

Original languageEnglish (US)
Pages (from-to)66-74
Number of pages9
JournalJournal of Atrial Fibrillation
Volume9
Issue number2
StatePublished - Aug 1 2016

Fingerprint

Anticoagulants
Atrial Fibrillation
Stroke
Vitamin K
Clinical Trials
Food-Drug Interactions
Pharmaceutical Preparations
Social Adjustment
Antithrombins
Manuscripts
Intracranial Hemorrhages
Proxy
Warfarin
Risk Reduction Behavior
Cardiac Arrhythmias
Thrombosis
Guidelines
Hemorrhage
Therapeutics

Keywords

  • Atrial fibrillation
  • DOACs
  • NVAF
  • Warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{9dbb7fa4aaca4ea393c7d7d87d2a6856,
title = "Reducing the risk of stroke in patients with nonvalvular atrial fibrillation with direct oral anticoagulants. is one of these not like the others",
abstract = "Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and increases risk of stroke by nearly 5-fold. While warfarin has been employed successfully to reduce the risk of stroke in these patients, there are a number of challenges with therapy. These include the need for therapeutic monitoring due to variability in patient response, frequent dose adjustments, numerous drug-drug, drug-food, and drug-disease interactions, and a heightened risk of thrombosis and bleeding due to these issues. Current guidelines recommend that the Vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs) should be used for thromboprophylaxis in patients with nonvalvular AF at risk for stroke or systemic embolic events. The DOACs include the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. In clinical trials these agents consistently demonstrated a reduction in the risks of hemorrhagic stroke and intracranial hemorrhage compared to VKA. Clinicians now must decide if there are meaningful differences between these agents in order to prescribe the best agent for an individual patient. Therefore, it is critical for clinicians to go beyond information provided in manuscript abstracts, and gain an understanding of the similarities and differences in clinical trial design, patient enrollment, and statistical analysis.",
keywords = "Atrial fibrillation, DOACs, NVAF, Warfarin",
author = "Dobesh, {Paul P.} and John Fanikos",
year = "2016",
month = "8",
day = "1",
language = "English (US)",
volume = "9",
pages = "66--74",
journal = "Journal of Atrial Fibrillation",
issn = "1941-6911",
publisher = "Cardiofront, Inc.",
number = "2",

}

TY - JOUR

T1 - Reducing the risk of stroke in patients with nonvalvular atrial fibrillation with direct oral anticoagulants. is one of these not like the others

AU - Dobesh, Paul P.

AU - Fanikos, John

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and increases risk of stroke by nearly 5-fold. While warfarin has been employed successfully to reduce the risk of stroke in these patients, there are a number of challenges with therapy. These include the need for therapeutic monitoring due to variability in patient response, frequent dose adjustments, numerous drug-drug, drug-food, and drug-disease interactions, and a heightened risk of thrombosis and bleeding due to these issues. Current guidelines recommend that the Vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs) should be used for thromboprophylaxis in patients with nonvalvular AF at risk for stroke or systemic embolic events. The DOACs include the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. In clinical trials these agents consistently demonstrated a reduction in the risks of hemorrhagic stroke and intracranial hemorrhage compared to VKA. Clinicians now must decide if there are meaningful differences between these agents in order to prescribe the best agent for an individual patient. Therefore, it is critical for clinicians to go beyond information provided in manuscript abstracts, and gain an understanding of the similarities and differences in clinical trial design, patient enrollment, and statistical analysis.

AB - Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and increases risk of stroke by nearly 5-fold. While warfarin has been employed successfully to reduce the risk of stroke in these patients, there are a number of challenges with therapy. These include the need for therapeutic monitoring due to variability in patient response, frequent dose adjustments, numerous drug-drug, drug-food, and drug-disease interactions, and a heightened risk of thrombosis and bleeding due to these issues. Current guidelines recommend that the Vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs) should be used for thromboprophylaxis in patients with nonvalvular AF at risk for stroke or systemic embolic events. The DOACs include the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. In clinical trials these agents consistently demonstrated a reduction in the risks of hemorrhagic stroke and intracranial hemorrhage compared to VKA. Clinicians now must decide if there are meaningful differences between these agents in order to prescribe the best agent for an individual patient. Therefore, it is critical for clinicians to go beyond information provided in manuscript abstracts, and gain an understanding of the similarities and differences in clinical trial design, patient enrollment, and statistical analysis.

KW - Atrial fibrillation

KW - DOACs

KW - NVAF

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84991744562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991744562&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84991744562

VL - 9

SP - 66

EP - 74

JO - Journal of Atrial Fibrillation

JF - Journal of Atrial Fibrillation

SN - 1941-6911

IS - 2

ER -